MX2022002547A - Una nueva plataforma de virus oncoliticos para tratar canceres con virus myxoma. - Google Patents
Una nueva plataforma de virus oncoliticos para tratar canceres con virus myxoma.Info
- Publication number
- MX2022002547A MX2022002547A MX2022002547A MX2022002547A MX2022002547A MX 2022002547 A MX2022002547 A MX 2022002547A MX 2022002547 A MX2022002547 A MX 2022002547A MX 2022002547 A MX2022002547 A MX 2022002547A MX 2022002547 A MX2022002547 A MX 2022002547A
- Authority
- MX
- Mexico
- Prior art keywords
- myxvs
- virus
- platform
- treat cancers
- myxoma
- Prior art date
Links
- 241000700562 Myxoma virus Species 0.000 title abstract 7
- 206010028980 Neoplasm Diseases 0.000 title 1
- 244000309459 oncolytic virus Species 0.000 title 1
- 102000013462 Interleukin-12 Human genes 0.000 abstract 2
- 108010065805 Interleukin-12 Proteins 0.000 abstract 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 2
- 229940117681 interleukin-12 Drugs 0.000 abstract 2
- 102000003390 tumor necrosis factor Human genes 0.000 abstract 2
- 102000004237 Decorin Human genes 0.000 abstract 1
- 108090000738 Decorin Proteins 0.000 abstract 1
- 108700019146 Transgenes Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24071—Demonstrated in vivo effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se divulga en este documento, en ciertas modalidades, virus Myxoma recombinantes (MYXV) y construcciones de ácido nucleico que codifican los MYXV recombinantes. En algunas modalidades, los MYXV son diseñados para inactivar o atenuar una actividad o nivel de expresión de una proteína M153. En algunas modalidades, los MYXV están diseñados para expresar uno o más transgenes tales como un factor de necrosis tumoral (TNF), interleucina 12 (IL-12) o decorina. También se divulga en este documento, en ciertas modalidades, métodos de uso de los MYXV. Algunas modalidades incluyen provee un MYXV como se describe en este documento a un sujeto en necesidad del mismo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962894925P | 2019-09-02 | 2019-09-02 | |
US201962944233P | 2019-12-05 | 2019-12-05 | |
PCT/US2020/049061 WO2021046125A1 (en) | 2019-09-02 | 2020-09-02 | A new oncolytic virus platform to treat cancers with myxoma virus |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022002547A true MX2022002547A (es) | 2022-05-18 |
Family
ID=74681244
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022002547A MX2022002547A (es) | 2019-09-02 | 2020-09-02 | Una nueva plataforma de virus oncoliticos para tratar canceres con virus myxoma. |
Country Status (11)
Country | Link |
---|---|
US (3) | US11117934B2 (es) |
EP (1) | EP4025228A4 (es) |
JP (1) | JP2022546539A (es) |
KR (1) | KR20220112241A (es) |
CN (1) | CN114615988A (es) |
AU (1) | AU2020342510A1 (es) |
CA (1) | CA3152779A1 (es) |
IL (1) | IL291009A (es) |
MX (1) | MX2022002547A (es) |
TW (1) | TW202122411A (es) |
WO (1) | WO2021046125A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11202100305SA (en) * | 2018-07-13 | 2021-02-25 | Univ Arizona State | Methods of treating cancer with tnf expressing myxoma virus |
WO2020051248A1 (en) * | 2018-09-05 | 2020-03-12 | Arizona Board Of Regents On Behalf Of Arizona State University | Oncolytic virus platform to treat hematological cancer |
WO2021046125A1 (en) | 2019-09-02 | 2021-03-11 | Arizona Board Of Regents On Behalf Of Arizona State University | A new oncolytic virus platform to treat cancers with myxoma virus |
JP2024508920A (ja) * | 2021-03-01 | 2024-02-28 | オンコミクス セラピューティクス,インク. | 多武装の粘液腫ウイルス |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2153284B1 (es) | 1998-06-10 | 2001-09-01 | Fundacion Para El Estudio Y De | Nuevo virus recombinante de mixoma atenuado y su uso en la preparacion de vacunas mixtas contra la mixomatosis y la enfermedad hemorragica de los conejos. |
WO2007143545A2 (en) * | 2006-06-01 | 2007-12-13 | Robarts Research Institute | Tnf signaling in myxoma virus treatments |
FR2946536B1 (fr) * | 2009-06-11 | 2011-07-29 | Agronomique Inst Nat Rech | Utilisation d'une souche attenuee de myxoma virus comme oncolytique |
US20130209406A1 (en) * | 2010-06-06 | 2013-08-15 | Benjamin R. tenOever | Recombinant rna viruses and uses thereof |
CA2836299A1 (en) * | 2011-04-15 | 2012-10-18 | Genelux Corporation | Clonal strains of attenuated vaccinia viruses and methods of use thereof |
WO2012171007A2 (en) | 2011-06-09 | 2012-12-13 | University Of Florida Research Foundation, Inc. | Methods for treating or preventing graft versus host disease |
NZ719934A (en) | 2013-11-28 | 2022-10-28 | Bavarian Nordic As | Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors |
CA2990133A1 (en) * | 2015-06-19 | 2017-03-09 | Sillajen, Inc. | Compositions and methods for viral embolization |
US11723932B2 (en) | 2016-01-11 | 2023-08-15 | Synlogic Operating Company, Inc. | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
EP3497208A4 (en) * | 2016-08-09 | 2020-03-11 | Turnstone Limited Partnership | ONCOLYTIC RHABDOVIRUS EXPRESSING IL12 |
SG11202100305SA (en) | 2018-07-13 | 2021-02-25 | Univ Arizona State | Methods of treating cancer with tnf expressing myxoma virus |
CA3109216A1 (en) | 2018-08-16 | 2020-02-20 | Musc Foundation For Research Development | Recombinant myxoma viruses and uses thereof |
WO2020051248A1 (en) | 2018-09-05 | 2020-03-12 | Arizona Board Of Regents On Behalf Of Arizona State University | Oncolytic virus platform to treat hematological cancer |
EP3946373A4 (en) | 2019-03-28 | 2023-01-11 | Arizona Board of Regents, a Body Corporate of the State of Arizona, acting for and on behalf of Arizona State University | ONCOLYTIC MYXOMA VIRUS EXPRESSING FAST P14 FOR TREATING BLOOD CANCER |
US20220296660A1 (en) | 2019-09-02 | 2022-09-22 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods and compositions for improving oncolytic virus infection for nonpermissive cancers |
WO2021046125A1 (en) | 2019-09-02 | 2021-03-11 | Arizona Board Of Regents On Behalf Of Arizona State University | A new oncolytic virus platform to treat cancers with myxoma virus |
-
2020
- 2020-09-02 WO PCT/US2020/049061 patent/WO2021046125A1/en unknown
- 2020-09-02 JP JP2022514014A patent/JP2022546539A/ja active Pending
- 2020-09-02 TW TW109130086A patent/TW202122411A/zh unknown
- 2020-09-02 KR KR1020227010537A patent/KR20220112241A/ko unknown
- 2020-09-02 AU AU2020342510A patent/AU2020342510A1/en active Pending
- 2020-09-02 US US17/010,711 patent/US11117934B2/en active Active
- 2020-09-02 CN CN202080076788.8A patent/CN114615988A/zh active Pending
- 2020-09-02 CA CA3152779A patent/CA3152779A1/en active Pending
- 2020-09-02 MX MX2022002547A patent/MX2022002547A/es unknown
- 2020-09-02 EP EP20861091.5A patent/EP4025228A4/en active Pending
-
2021
- 2021-06-24 US US17/357,624 patent/US20210324014A1/en not_active Abandoned
-
2022
- 2022-03-01 IL IL291009A patent/IL291009A/en unknown
- 2022-08-22 US US17/893,052 patent/US20230025706A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20210324014A1 (en) | 2021-10-21 |
JP2022546539A (ja) | 2022-11-04 |
US11117934B2 (en) | 2021-09-14 |
WO2021046125A1 (en) | 2021-03-11 |
AU2020342510A1 (en) | 2022-03-24 |
US20230025706A1 (en) | 2023-01-26 |
EP4025228A4 (en) | 2023-09-06 |
EP4025228A1 (en) | 2022-07-13 |
US20210061864A1 (en) | 2021-03-04 |
IL291009A (en) | 2022-05-01 |
TW202122411A (zh) | 2021-06-16 |
CN114615988A (zh) | 2022-06-10 |
KR20220112241A (ko) | 2022-08-10 |
CA3152779A1 (en) | 2021-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022002547A (es) | Una nueva plataforma de virus oncoliticos para tratar canceres con virus myxoma. | |
SA520412637B1 (ar) | B7 الفيروس الغدي الحال للورم المشفِّر لبروتين | |
Patil et al. | Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients | |
MX2019000252A (es) | Administracion viral oncolitica pseudotipada de polipeptidos terapeuticos. | |
Kotwal | Poxviral mimicry of complement and chemokine system components: what’s the end game? | |
MX2021002415A (es) | Celulas madre hematopoyeticas modificadas geneticamente y usos de las mismas. | |
Gambini et al. | Replication-competent herpes simplex virus retargeted to HER2 as therapy for high-grade glioma | |
MY140829A (en) | Chimeric adenoviruses for use in cancer treatment | |
Hensley et al. | Type I interferon inhibits antibody responses induced by a chimpanzee adenovirus vector | |
AU2018273963A1 (en) | Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells | |
MX2021008392A (es) | Neoantígenos prostaticos y sus usos. | |
NZ591733A (en) | Recombinant newcastle disease virus comprising a transgene encoding a fusion protein comprising a binding domain and a heterologous domain comprising an enzyme | |
MX2019013836A (es) | Vectores virales que codifican variantes del factor de coagulacion ix (fix) recombinantes con mayor expresion para la terapia genica de hemofilia b. | |
MXPA02006888A (es) | Flavivirus recombinantes y metodos para utilizar los mismos. | |
MX2021008146A (es) | Polinucleotidos de arn encapsulado y metodos de uso. | |
WO2011130749A3 (en) | Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors | |
MX2021014525A (es) | Adenovirus modificados. | |
MX2010008370A (es) | Paramixovirus oncoliticos atenuados que codifican citoquinas de aves. | |
MX2020013901A (es) | Virus oncolítico o antígeno que presenta terapia contra el cáncer mediada por células usando interferón tipo i y lingado de cd40. | |
MX2022010588A (es) | Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2. | |
Mejías-Pérez et al. | Development of a safe and effective vaccinia virus oncolytic vector WR-Δ4 with a set of gene deletions on several viral pathways | |
MX2021000421A (es) | Métodos y composiciones que usan células dendríticas recombinantes para el tratamiento del cáncer. | |
MX2020009541A (es) | Virus vaccinia oncolitico que expresa bloqueo de punto de control inmunologico para inmunoterapia de cancer. | |
Zhang et al. | Tanapoxvirus lacking a neuregulin-like gene regresses human melanoma tumors in nude mice | |
SA521422601B1 (ar) | فيروس ربدي ناتج عن عودة الارتباط الجيني يشفر ccl21 |